A finalized regulation for contract year 2027 does something narrower than it sounds: it converts a set of temporary Medicare program instructions into permanent federal law. The rule locks in the elimination of the Part D coverage gap, a reduced annual out-of-pocket threshold, and the removal of cost sharing once an enrollee reaches the catastrophic phase of drug spending. CMS says the move is necessary because the program-instruction authority Congress gave it under the Inflation Reduction Act to run these changes through 2026 is expiring. The agency has not yet published the dollar figures that will define 2027 coverage.
The Contract Year 2027 final rule and why CMS is acting now
The rule in question is CMS’s Contract Year 2027 Medicare Advantage and Part D final rule, which covers everything from Star Ratings measures to marketing rules for the two programs. One section, devoted to implementing the Inflation Reduction Act, contains the provision drawing the most attention from retirees: the permanent codification of the Part D benefit redesign Congress ordered in 2022. CMS states the reason for acting now directly. The agency had been running the IRA’s drug-benefit changes through program instructions, the annual guidance memos it uses to implement policy without full rulemaking, and that instruction authority is expiring.
Codifying a policy means writing it into the Code of Federal Regulations rather than leaving it inside a memo CMS can revise, decline to reissue, or that a future administration could simply stop enforcing. In the fact sheet accompanying the final rule, CMS says its program-instruction authority over the IRA’s Part D changes runs only through 2026, and that codifying the policy for 2027 and beyond is what closes that gap in legal authority.
Free retirement updates: A quiet rule change can shrink a Social Security or Medicare check with no warning. The free Retirement Shield newsletter catches these early. Get it free.
How the coverage gap’s elimination moves from guidance to regulation
The coverage gap, long nicknamed the donut hole, is not new territory for CMS. Section 11201 of the Inflation Reduction Act eliminated the coverage gap phase of the Part D benefit starting with the 2025 plan year, meaning every Part D enrollee has already gone two full years without hitting that mid-benefit spending cliff. What CMS finalized this year does not create that elimination; it locks in the version of the Part D benefit that already exists, so the coverage-gap phase cannot simply reappear because an agency chooses not to renew a set of instructions.
Three specific mechanisms are named in the final rule as being carried into permanent regulation: the elimination of the coverage gap phase itself, a reduced annual out-of-pocket threshold that determines when an enrollee reaches the benefit’s catastrophic phase, and the removal of any cost sharing once an enrollee is in that catastrophic phase. Under the design Congress replaced, enrollees paid a percentage of drug costs even after clearing the old catastrophic threshold; the redesign, now permanent regulation rather than yearly guidance, keeps that cost sharing at zero.
The distinction matters procedurally as much as substantively. A program instruction can be reissued, narrowed, or allowed to lapse at CMS’s discretion from one year to the next. A regulation in the Code of Federal Regulations can only be undone through a new rulemaking, with public notice and a comment period, the same process CMS used to finalize this rule in the first place. That is a materially higher bar than declining to send out a memo, and it is the practical effect of moving these Part D provisions out of guidance and into regulation for 2027 and beyond.
For an enrollee who already crossed into Part D’s catastrophic phase last year, day-to-day costs will not change on their own because of this rule; the coverage gap has not applied to any enrollee since January 2025, regardless of whether the underlying authority sat in a program instruction or a federal regulation. What changes is durability, not immediate experience: a policy that survived only because CMS kept renewing an instruction now survives because CMS ran the change through full notice-and-comment rulemaking, the same process it would take to reverse it.
The Manufacturer Discount Program and the unresolved 2027 dollar figures
The same codification folds in the Manufacturer Discount Program, which replaced the Coverage Gap Discount Program on January 1, 2025, as the mechanism requiring drug manufacturers to discount brand-name drugs for Part D enrollees. Where the earlier program applied only inside the now-eliminated coverage gap, the Manufacturer Discount Program’s discount obligations extend across the redesigned benefit, another piece CMS says it is writing into permanent rule rather than leaving to annual instruction.
What the final rule does not settle is money. CMS’s own Medicare & You 2027 handbook, mailed to enrollees ahead of this fall’s open enrollment, states plainly that the premium amounts, drug costs, and income limits for 2027 were not available at the time of printing. The mechanism now has the force of regulation; the dollar figures that will apply it, including the specific out-of-pocket threshold the rule references, still do not exist in public form.
The gap between rule and figure is visible on Medicare’s own site. As of this year, Medicare’s page on help with drug costs lists a 2026 out-of-pocket figure of $2,100 in total drug costs, the point after which an enrollee in the Extra Help program pays nothing more for the rest of that year. No 2027 version of that page exists yet, and CMS has not said when it will replace it.
That leaves Medicare Advantage plans, Part D sponsors, and Part D enrollees with a benefit whose shape is now fixed in federal regulation but whose price is not yet set. Insurers building 2027 plan bids and premiums are working against out-of-pocket parameters CMS has not yet released, and enrollees comparing plans during this fall’s open enrollment will do so without the specific threshold the codified rule is built around. The coverage gap’s elimination is settled law; what it will cost enrollees to reach the protections built around it in 2027 remains a question only CMS’s still-unpublished figures can answer.
This article was produced with AI assistance and reviewed by The Money Overview editorial team.
More Financial Reading
